Commerzbank Analysts Give Fresenius SE & Co KGaA (FRE) a €83.00 Price Target

Commerzbank set a €83.00 ($96.51) price objective on Fresenius SE & Co KGaA (FRA:FRE) in a research note published on Tuesday. The firm currently has a buy rating on the stock.

FRE has been the subject of a number of other research reports. Barclays set a €80.00 ($93.02) price objective on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a report on Tuesday. Independent Research set a €78.00 ($90.70) price objective on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a report on Monday, July 16th. Berenberg Bank set a €81.85 ($95.17) price objective on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a report on Wednesday, July 25th. Goldman Sachs Group set a €72.00 ($83.72) price objective on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a report on Tuesday, July 31st. Finally, Deutsche Bank set a €82.00 ($95.35) price objective on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a report on Thursday, July 19th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of €75.94 ($88.31).

Shares of FRA FRE opened at €54.90 ($63.84) on Tuesday. Fresenius SE & Co KGaA has a 1 year low of €60.16 ($69.95) and a 1 year high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Read More: Consumer behavior in bull markets

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply